Compare $BCRX vs $VRDN | Chartloom

Compare

$BCRX vs $VRDN

BioCryst Pharmaceuticals Inc · Viridian Therapeutics Inc

BCRX

BioCryst Pharmaceuticals Inc

VRDN

Viridian Therapeutics Inc

Compare $BCRX vs $VRDN

Comparing BioCryst Pharmaceuticals Inc and Viridian Therapeutics Inc

BCRXBioCryst Pharmaceuticals Inc

VRDNViridian Therapeutics Inc

BCRXBioCryst Pharmaceuticals Inc

Market cap

$2.17B

P/E (TTM)

—

Forward P/E (NTM)

16.67x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

68.7%

YTD performance

14.0%

52W performance

17.4%

FCF yield

17.9%

VRDNViridian Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.59x

Rev growth (TTM)

23220.3%

YTD performance

-39.2%

52W performance

-12.6%

FCF yield

-16.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCRX

VRDN

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

VRDN

Viridian Therapeutics Inc

Market Cap

BCRX$2.17B

VRDN$2.06B

Enterprise Value

BCRX$2.84B

VRDN$2.25B

Price

BCRX$8.55

VRDN$18.66

P/E Ratio

BCRXN/A

VRDNN/A

P/S Ratio

BCRX2.31x

VRDN28.97x

EV/Sales

BCRX3.02x

VRDN31.65x

EV/EBITDA

BCRX6.85x

VRDN0.00x

P/B Ratio

BCRX62.13x

VRDN3.58x

P/FCF Ratio

BCRX5.59x

VRDNN/A

EV/FCF

BCRX7.32x

VRDN-6.72x

PEG Ratio

BCRXN/A

VRDNN/A

Forward P/E (NTM)

BCRX16.67x

VRDNN/A

Forward P/S (NTM)

BCRX3.13x

VRDN14.59x

Revenue (TTM)

BCRX$941M

VRDN$71M

Revenue Growth (YoY)

BCRX68.7%

VRDN23220.3%

Forward Rev Growth

BCRX3.9%

VRDN729.0%

Gross Margin (TTM)

BCRX97.8%

VRDN2.4%

Operating Margin (TTM)

BCRX0.0%

VRDN0.0%

EBITDA Margin (TTM)

BCRX41.1%

VRDN-569.0%

Net Margin (TTM)

BCRX-40.9%

VRDN-544.1%

FCF Margin (TTM)

BCRX41.3%

VRDN-471.0%

Net Income (TTM)

BCRX$-385M

VRDN$-387M

FCF (TTM)

BCRX$388M

VRDN$-335M

EPS (TTM)

BCRX-$1.45

VRDN-$3.59

ROE (TTM)

BCRX-32882.0%

VRDN-6135.0%

ROA (TTM)

BCRX-7758.0%

VRDN-4603.0%

ROIC (TTM)

BCRX-10666.0%

VRDN-5041.0%

Cash

BCRX$155M

VRDN$165M

Debt

BCRX$824M

VRDN$356M

Net Cash/Debt

BCRX$-669M

VRDN$-191M

Current Ratio (TTM)

BCRX2.32x

VRDN16.95x

Quick Ratio (TTM)

BCRX2.22x

VRDN16.56x

Debt/Equity (TTM)

BCRX2.26x

VRDN0.54x

Debt/Assets (TTM)

BCRX0.0%

VRDN0.0%

Interest Coverage (TTM)

BCRXN/A

VRDNN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

VRDN0.00x

Beta

BCRX0.54

VRDN1.11

52W Performance

BCRX17.4%

VRDN-12.6%

YTD Performance

BCRX14.0%

VRDN-39.2%

% from 52W High

BCRX-23.8%

VRDN-45.6%

% from 52W Low

BCRX42.5%

VRDN41.6%

Asset Turnover (TTM)

BCRX1.90x

VRDN0.08x

FCF Yield (TTM)

BCRX17.9%

VRDN-16.3%

Earnings Yield (TTM)

BCRX-17.7%

VRDN-18.8%

Dividend Yield (TTM)

BCRXN/A

VRDNN/A

Rule of 40

BCRX110.0

VRDN22,749.3

EV/GP/RG

BCRX0.74

VRDN8.67

Ticker research

View BCRX research View VRDN research

Metric	BCRX BioCryst Pharmaceuticals Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.17B	$2.06B
Enterprise Value	$2.84B	$2.25B
Price	$8.55	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	28.97x
EV/Sales	3.02x	31.65x
EV/EBITDA	6.85x	0.00x
P/B Ratio	62.13x	3.58x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	14.59x
Revenue & Growth
Revenue (TTM)	$941M	$71M
Revenue Growth (YoY)	68.7%	23220.3%
Forward Rev Growth	3.9%	729.0%
Profitability
Gross Margin (TTM)	97.8%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	-569.0%
Net Margin (TTM)	-40.9%	-544.1%
FCF Margin (TTM)	41.3%	-471.0%
Net Income (TTM)	$-385M	$-387M
FCF (TTM)	$388M	$-335M
EPS (TTM)	-$1.45	-$3.59
ROE (TTM)	-32882.0%	-6135.0%
ROA (TTM)	-7758.0%	-4603.0%
ROIC (TTM)	-10666.0%	-5041.0%
Financial Health
Cash	$155M	$165M
Debt	$824M	$356M
Net Cash/Debt	$-669M	$-191M
Current Ratio (TTM)	2.32x	16.95x
Quick Ratio (TTM)	2.22x	16.56x
Debt/Equity (TTM)	2.26x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	1.11
52W Performance	17.4%	-12.6%
YTD Performance	14.0%	-39.2%
% from 52W High	-23.8%	-45.6%
% from 52W Low	42.5%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.08x
FCF Yield (TTM)	17.9%	-16.3%
Earnings Yield (TTM)	-17.7%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	22,749.3
EV/GP/RG	0.74	8.67
Ticker research	View BCRX research	View VRDN research

Valuation

P/S Ratio

BCRX

2.31x

VRDN

28.97x

EV/FCF

VRDN

-6.72x

BCRX

7.32x

Growth & revenue

Revenue Growth TTM

VRDN

23220.3%

BCRX

68.7%

Forward Revenue Growth

VRDN

729.0%

BCRX

3.9%

Profitability & performance

Gross Margin

BCRX

97.8%

VRDN

2.4%

ROE

VRDN

-6135.0%

BCRX

-32882.0%

FCF Yield %

BCRX

17.9%

VRDN

-16.3%

52-Week Performance

BCRX

17.4%

VRDN

-12.6%

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

VRDN

Viridian Therapeutics Inc

Market Cap

BCRX$2.17B

VRDN$2.06B

Enterprise Value

BCRX$2.84B

VRDN$2.25B

Price

BCRX$8.55

VRDN$18.66

P/E Ratio

BCRXN/A

VRDNN/A

P/S Ratio

BCRX2.31x

VRDN28.97x

EV/Sales

BCRX3.02x

VRDN31.65x

EV/EBITDA

BCRX6.85x

VRDN0.00x

P/B Ratio

BCRX62.13x

VRDN3.58x

P/FCF Ratio

BCRX5.59x

VRDNN/A

EV/FCF

BCRX7.32x

VRDN-6.72x

PEG Ratio

BCRXN/A

VRDNN/A

Forward P/E (NTM)

BCRX16.67x

VRDNN/A

Forward P/S (NTM)

BCRX3.13x

VRDN14.59x

Revenue (TTM)

BCRX$941M

VRDN$71M

Revenue Growth (YoY)

BCRX68.7%

VRDN23220.3%

Forward Rev Growth

BCRX3.9%

VRDN729.0%

Gross Margin (TTM)

BCRX97.8%

VRDN2.4%

Operating Margin (TTM)

BCRX0.0%

VRDN0.0%

EBITDA Margin (TTM)

BCRX41.1%

VRDN-569.0%

Net Margin (TTM)

BCRX-40.9%

VRDN-544.1%

FCF Margin (TTM)

BCRX41.3%

VRDN-471.0%

Net Income (TTM)

BCRX$-385M

VRDN$-387M

FCF (TTM)

BCRX$388M

VRDN$-335M

EPS (TTM)

BCRX-$1.45

VRDN-$3.59

ROE (TTM)

BCRX-32882.0%

VRDN-6135.0%

ROA (TTM)

BCRX-7758.0%

VRDN-4603.0%

ROIC (TTM)

BCRX-10666.0%

VRDN-5041.0%

Cash

BCRX$155M

VRDN$165M

Debt

BCRX$824M

VRDN$356M

Net Cash/Debt

BCRX$-669M

VRDN$-191M

Current Ratio (TTM)

BCRX2.32x

VRDN16.95x

Quick Ratio (TTM)

BCRX2.22x

VRDN16.56x

Debt/Equity (TTM)

BCRX2.26x

VRDN0.54x

Debt/Assets (TTM)

BCRX0.0%

VRDN0.0%

Interest Coverage (TTM)

BCRXN/A

VRDNN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

VRDN0.00x

Beta

BCRX0.54

VRDN1.11

52W Performance

BCRX17.4%

VRDN-12.6%

YTD Performance

BCRX14.0%

VRDN-39.2%

% from 52W High

BCRX-23.8%

VRDN-45.6%

% from 52W Low

BCRX42.5%

VRDN41.6%

Asset Turnover (TTM)

BCRX1.90x

VRDN0.08x

FCF Yield (TTM)

BCRX17.9%

VRDN-16.3%

Earnings Yield (TTM)

BCRX-17.7%

VRDN-18.8%

Dividend Yield (TTM)

BCRXN/A

VRDNN/A

Rule of 40

BCRX110.0

VRDN22,749.3

EV/GP/RG

BCRX0.74

VRDN8.67

Ticker research

View BCRX research View VRDN research

Metric	BCRX BioCryst Pharmaceuticals Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.17B	$2.06B
Enterprise Value	$2.84B	$2.25B
Price	$8.55	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	28.97x
EV/Sales	3.02x	31.65x
EV/EBITDA	6.85x	0.00x
P/B Ratio	62.13x	3.58x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	14.59x
Revenue & Growth
Revenue (TTM)	$941M	$71M
Revenue Growth (YoY)	68.7%	23220.3%
Forward Rev Growth	3.9%	729.0%
Profitability
Gross Margin (TTM)	97.8%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	-569.0%
Net Margin (TTM)	-40.9%	-544.1%
FCF Margin (TTM)	41.3%	-471.0%
Net Income (TTM)	$-385M	$-387M
FCF (TTM)	$388M	$-335M
EPS (TTM)	-$1.45	-$3.59
ROE (TTM)	-32882.0%	-6135.0%
ROA (TTM)	-7758.0%	-4603.0%
ROIC (TTM)	-10666.0%	-5041.0%
Financial Health
Cash	$155M	$165M
Debt	$824M	$356M
Net Cash/Debt	$-669M	$-191M
Current Ratio (TTM)	2.32x	16.95x
Quick Ratio (TTM)	2.22x	16.56x
Debt/Equity (TTM)	2.26x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	1.11
52W Performance	17.4%	-12.6%
YTD Performance	14.0%	-39.2%
% from 52W High	-23.8%	-45.6%
% from 52W Low	42.5%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.08x
FCF Yield (TTM)	17.9%	-16.3%
Earnings Yield (TTM)	-17.7%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	22,749.3
EV/GP/RG	0.74	8.67
Ticker research	View BCRX research	View VRDN research